PATENTS

1647

10441Z

Date: September 8, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nicholas K. Haywald? Examiner: C. Saoud

Serial No.: 09/349,954

July 8, 199 Filing Date:

A NOVEL GROWTH FACTOR

GENETIC SEQUENCE ENCODING SAME

Assistant Commissioner for Patents

Washington, D.C. 20231

Art Unit:

Docket:

AMENDMENT

Sir:

TECH CENTER 1600/2900 In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 9, 2000, please amend the specification as follows:

IN THE BRIEF DESCRIPTION OF FIGURES:

<u>Page 9, line 22</u>, after "sequence" insert --comparison of SOM175 (QUERY) protein sequence fragments [SEQ ID NO:4] with VEGF₁₆₅ (SUBJCT) protein sequence fragments [SEQ ID NO:2]--.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on September 8, 2000.

Dated: September 8, 2000

bb\F:\WORK\536\10441zMISC\10441z.am1

NO:1]-- after "SOM175 cDNA" insert --[SEQ ID NO:3]--.

Page 9, line 26, after "VEGF₁₆₅" insert --[SEQ ID NO:1]-- after "SOM175" insert --[SEQ ID NO:3]--; after "splice variants" insert -- SOM175-e6 [SEQ ID NO:5]; SOM175-e6&7 [SEQ ID NO:7]; SOM175-e4 [SEQ ID NO:9]--.

Page 9, line 29, after "VEGF₁₆₅" insert --[SEQ ID NO:2]--; after "SOM175" insert --[SEQ ID NO:4]--.

Page 10, line 4, after "human SOM175" insert --[SEQ ID
NO:15]--.

Page 10, line 8, after "clones" insert --[SEQ ID NOS:16, 17 and 18]--.

Page 10, line 18, after "mVRF $_{167}$ " insert --[SEQ ID NO:19]--; after "hVRF $_{167}$ " insert --[SEQ ID NO:20]--; after "mVRF $_{186}$ " insert --[SEQ ID NO:21]--; after "hVRF $_{186}$ " insert --[SEQ ID NO:22]--.

Page 10, line 23, after "mVRF $_{167}$ " insert --[SEQ ID NO:19]--; after "mVEGF $_{188}$ " insert --[SEQ ID NO:23]--.

After Page 35, please insert the substitute Sequence Listing and renumber the specification and claim pages accordingly.

REMARKS

In accordance with 37 C.F.R. §1.821(d), applicants have amended the Brief Description of the Figures to provide reference to sequence identifiers and comparisons thereof in Figures 3-11.